To include your compound in the COVID-19 Resource Center, submit it here.

Biogen licenses Karyopharm neurology candidates, reports earnings

Biogen Inc. (NASDAQ:BIIB) licensed exclusive, worldwide rights to KPT-350 and related assets from Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to treat neurological and neurodegenerative diseases and reported a 34% rise

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE